Cancer Breakthroughs & Clinical Research Tracker 2026–2027
A continuously maintained research resource tracking important cancer breakthroughs, clinical trial results, precision oncology developments, immunotherapies, molecularly targeted treatments, cancer vaccines, liquid biopsy technologies and artificial intelligence in oncology.
Cancer research is advancing across multiple scientific disciplines. Precision medicine is expanding treatment options for biomarker-defined tumors, immunotherapy is reaching new patient populations, and technologies such as circulating tumor DNA (ctDNA), artificial intelligence (AI) and personalized neoantigen vaccines are changing the possibilities for cancer detection and treatment.
The Cancer Breakthroughs & Clinical Research Tracker 2026–2027 brings these developments together in one research-focused resource.
Unlike a conventional news roundup, this tracker classifies developments according to their research and regulatory status. It distinguishes FDA-approved treatments from positive clinical trial results, ongoing investigations and preclinical discoveries.
- FDA oncology drug approvals and expanded indications.
- Phase I, II and III cancer clinical trials.
- Precision oncology and molecular biomarkers.
- Immunotherapy, CAR T-cell therapy and antibody-drug conjugates.
- Personalized cancer vaccines and RNA medicines.
- Liquid biopsy, ctDNA and minimal residual disease.
- AI-assisted cancer diagnostics and drug discovery.
- Emerging cancer targets, resistance mechanisms and experimental treatments.
Research cutoff: Initial tracker publication November 6, 2026. The most recent FDA notifications and selected research publications are included below. This is an editorially maintained resource, not an automatically updating clinical database.
- Research dashboard
- Tracker methodology and evidence classification
- FDA oncology approvals: July–October 2026
- Major clinical trial results
- Clinical trial monitoring list
- Precision oncology and biomarkers
- Immunotherapy and cell therapy
- Personalized cancer vaccines and RNA medicines
- Liquid biopsy and MRD
- AI in cancer research
- Cancer resistance and new therapeutic targets
- 2027 research watchlist
- Tracker update log
- Frequently asked questions
- References and research databases
1. Cancer Research Dashboard 2026–2027
This dashboard summarizes the main areas covered by the tracker. Counts are not presented as total industry-wide study or approval counts; individual records are added as they are verified.
FDA-approved treatment developments
Coverage: Selected new approvals and expanded indications announced between July 1 and October 26, 2026.
Key development: Additional biomarker-directed treatments for prostate, breast, lung, pancreatic, colorectal and other cancers.
Phase III clinical research
Coverage: Major late-stage clinical trial readouts and publications.
Key development: Individualized mRNA cancer vaccine research in melanoma and novel T-cell engager combinations in small-cell lung cancer.
Early-stage clinical research
Coverage: Phase I and II studies that offer new insight into emerging therapeutic approaches.
Key development: Personalized neoantigen-targeting vaccine research in ovarian cancer.
Emerging technology
Coverage: AI, liquid biopsy, ctDNA, MRD, RNA medicines and novel therapeutic platforms.
Key development: Greater integration of molecular profiling and individualized treatment strategies.
2. Tracker Methodology: How to Interpret Cancer Research
Not all cancer breakthroughs have the same evidentiary significance. A positive laboratory experiment is not equivalent to a successful human clinical trial, and a successful clinical trial is not automatically an FDA-approved treatment.
Evidence and development classifications
FDA approved
A treatment has received FDA approval for a specified cancer type, indication and patient population. Approval does not imply suitability for every patient with that cancer.
Accelerated approval
The FDA has granted accelerated approval based on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. Confirmatory evidence may still be required.
Phase III clinical trial
A late-stage study generally designed to evaluate efficacy and safety in a larger patient population. Positive results may support a regulatory submission, but the trial does not itself constitute regulatory approval.
Phase II clinical trial
An intermediate-stage clinical study evaluating treatment activity and safety. Results can support further development but do not establish definitive clinical benefit.
Phase I clinical trial
An early clinical study primarily evaluating safety, tolerability, dose and initial biological activity.
Preclinical research
Laboratory and animal-model research conducted before human clinical testing. Findings remain experimental.
3. FDA Oncology Approvals and Expanded Indications: July–October 2026
This section records selected FDA oncology and hematology notifications after the AACR Cancer Progress Report 2026 cutoff of June 30, 2026.
The entries below are not a complete list of every oncology regulatory action. FDA notes that not every oncology approval or label update receives a separate approval notification. The official FDA oncology approval database remains the primary reference.
October 2026
Talazoparib + enzalutamide — HRR-mutated prostate cancer
FDA approved talazoparib (Talzenna) in combination with enzalutamide for adults with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer carrying homologous recombination repair (HRR) gene mutations, identified through an FDA-authorized test.
Research significance: Expands biomarker-directed combination therapy for selected patients with metastatic prostate cancer.
Pembrolizumab — TMB-high solid tumors
FDA granted traditional approval for pembrolizumab (Keytruda), or pembrolizumab with berahyaluronidase alfa-pmph, for eligible adult and pediatric patients with unresectable or metastatic tumor mutational burden-high solid tumors, defined by at least 13 mutations per megabase using an FDA-authorized test, after prior treatment and when no satisfactory alternative treatment options are available.
Research significance: Reinforces the importance of tumor biomarkers that may guide treatment across different tissue types.
Dostarlimab — locally advanced rectal cancer
FDA granted accelerated approval to dostarlimab (Jemperli) for adults with stage II or III locally advanced rectal cancer that is microsatellite instability-high or mismatch repair deficient, as determined by an FDA-authorized test.
Research significance: Highlights the importance of identifying mismatch repair deficiency and microsatellite instability before selecting treatment.
Anktiva — non-muscle-invasive bladder cancer
FDA expanded the indication for nogapendekin alfa inbakicept-pmln (Anktiva), in combination with BCG, to include patients with high-grade papillary-only tumors in BCG-unresponsive non-muscle-invasive bladder cancer.
Research significance: Expands an existing immunotherapy-based treatment option to an additional bladder cancer population.
Atezolizumab + chemotherapy — stage III dMMR colon cancer
FDA approved atezolizumab (Tecentriq) in combination with fluoropyrimidine- and oxaliplatin-based chemotherapy for adjuvant treatment of eligible patients with stage III mismatch repair-deficient colon cancer.
Research significance: Represents an important development in biomarker-guided adjuvant immunotherapy for selected colorectal cancer patients.
Tucatinib + trastuzumab + pertuzumab — HER2-positive breast cancer
FDA approved tucatinib (Tukysa) combined with trastuzumab and pertuzumab for maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.
Research significance: Adds a treatment combination for a defined HER2-positive breast cancer population.
Pirtobrutinib — previously untreated CLL/SLL
FDA approved pirtobrutinib (Jaypirca) for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma without a known 17p deletion.
Research significance: Extends the clinical use of a targeted BTK inhibitor into an earlier treatment setting for the specified population.
September 2026
Belzutifan + lenvatinib — advanced renal cell carcinoma
FDA approved the combination for adults with advanced renal cell carcinoma with a clear-cell component following treatment with a PD-1 or PD-L1 inhibitor.
Research significance: Adds a combination option for selected patients whose disease has progressed after immune checkpoint treatment.
Lirafugratinib — FGFR2-altered cholangiocarcinoma
FDA approved lirafugratinib (Lyrfigtu) for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 gene fusion or other rearrangement.
Research significance: Demonstrates the importance of identifying actionable molecular alterations in uncommon cancers.
Imlunestrant + abemaciclib — ESR1-mutated breast cancer
FDA approved imlunestrant (Inluriyo) with abemaciclib (Verzenio) for eligible adults with advanced or metastatic disease following at least one line of endocrine therapy.
Research significance: Reinforces the role of acquired endocrine resistance mutations in treatment selection.
Sevabertinib — HER2-mutated non-small cell lung cancer
FDA granted accelerated approval to sevabertinib (Hyrnuo) for selected adults with locally advanced or metastatic non-squamous NSCLC carrying HER2 tyrosine kinase domain activating mutations.
Research significance: Adds a targeted option for a molecularly defined NSCLC population.
Camizestrant + CDK4/6 inhibitor — ESR1-mutated breast cancer
FDA granted accelerated approval to camizestrant (Etcamah) with a CDK4/6 inhibitor for eligible patients with locally advanced or metastatic disease following detection of an ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor treatment.
Research significance: Illustrates how serial biomarker testing may inform treatment decisions as resistance develops.
August 2026
Daraxonrasib — metastatic pancreatic adenocarcinoma
FDA approved daraxonrasib (RASONQUE), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
Research significance: An important development in targeting RAS-driven pancreatic cancer, a historically difficult area of drug development.
Zanidatamab + tislelizumab-based treatment — HER2-positive gastroesophageal cancer
FDA approved zanidatamab (Ziihera) in specified first-line combinations for eligible adults with HER2-positive unresectable locally advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma.
Research significance: Expands HER2-directed treatment strategies in gastroesophageal malignancies.
Iberdomide combination — multiple myeloma
FDA granted accelerated approval to iberdomide (Zenbexus) with daratumumab and hyaluronidase-fihj and dexamethasone for eligible adults with multiple myeloma previously treated with at least one line of therapy, including a proteasome inhibitor and an immunomodulatory agent.
Research significance: Adds a new combination strategy to the treatment landscape for multiple myeloma.
Vusolimogene oderparepvec + nivolumab — advanced melanoma
FDA granted accelerated approval to the genetically modified oncolytic viral therapy vusolimogene oderparepvec (Tudriqev) with nivolumab for adults with unresectable advanced cutaneous melanoma that progressed following a PD-1-blocking antibody-based regimen.
Research significance: Illustrates the potential of combining oncolytic viral approaches with immune checkpoint blockade in selected patients.
July 2026
Lutetium Lu 177 vipivotide tetraxetan (Pluvicto) + ARPI
FDA approved Pluvicto with androgen receptor pathway inhibitor therapy for eligible adults with PSMA-positive metastatic androgen pathway modulation-naïve or -sensitive prostate cancer.
Research significance: Extends PSMA-targeted radioligand therapy into an earlier metastatic treatment setting for eligible patients.
Zidesamtinib — ROS1-positive lung cancer
FDA approved zidesamtinib (Jideytro) for adults with locally advanced or metastatic ROS1-positive NSCLC who have received at least one prior ROS1 tyrosine kinase inhibitor.
Research significance: Expands targeted treatment options for patients with ROS1-positive disease, including those previously treated with another ROS1 inhibitor.
Gedatolisib + fulvestrant, with or without palbociclib
FDA approved gedatolisib (Revtorpyk) in combination with fulvestrant, with or without palbociclib, for specified adults with locally advanced or metastatic HR-positive, HER2-negative breast cancer without a detected PIK3CA mutation following progression on endocrine treatment.
Research significance: Adds a pathway-directed combination approach for a biomarker-defined breast cancer population.
Selpercatinib — RET fusion-positive solid tumors
FDA granted traditional approval to selpercatinib (Retevmo) for eligible adult and pediatric patients aged two years and older with locally advanced or metastatic RET fusion-positive solid tumors that have progressed following prior systemic treatment or have no satisfactory alternative treatment options.
Research significance: Strengthens biomarker-guided, tissue-agnostic precision oncology.
Pembrolizumab + enfortumab vedotin — muscle-invasive bladder cancer
FDA expanded the eligible population for pembrolizumab (Keytruda) with enfortumab vedotin (Padcev), as neoadjuvant treatment followed by adjuvant treatment after cystectomy, to adults with muscle-invasive bladder cancer who are candidates for cystectomy.
Research significance: Broadens the use of perioperative immunotherapy and antibody-drug conjugate treatment in muscle-invasive bladder cancer.
Regulatory note: These records describe US FDA indications as announced on the dates shown. They do not establish availability, approval or reimbursement in other countries. Always consult the current prescribing information and relevant companion diagnostic requirements.
4. Major Cancer Clinical Trial Results: 2026
This section follows notable clinical research results that may influence future treatment guidelines or regulatory decisions.
INTerpath-001: Personalized mRNA vaccine + pembrolizumab in melanoma
Merck and Moderna reported positive Phase III findings for intismeran autogene, an individualized mRNA-based neoantigen therapy, combined with pembrolizumab in patients with completely resected high-risk stage IIB–IV melanoma.
At the ESMO Congress 2026, the 24-month recurrence-free survival rate was:
- 82.2% with intismeran plus pembrolizumab.
- 70.0% with placebo plus pembrolizumab.
The hazard ratio for recurrence or death was 0.58 (95% CI 0.45–0.75; p<0.001).
Research significance: A major Phase III milestone for individualized mRNA-based cancer immunotherapy.
Regulatory status: Investigational combination at the reporting cutoff; positive Phase III results do not themselves constitute FDA approval.
DeLLphi-305: Tarlatamab + durvalumab in small-cell lung cancer
The Phase III DeLLphi-305 study evaluated tarlatamab, a bispecific T-cell engager, combined with durvalumab as first-line maintenance treatment in extensive-stage small-cell lung cancer following initial treatment with durvalumab, platinum-based chemotherapy and etoposide.
Results published in The New England Journal of Medicine showed:
- Median overall survival: 21.1 months versus 12.7 months.
- Hazard ratio for death: 0.42.
- Median progression-free survival: 7.4 months versus 1.9 months.
- Hazard ratio for progression or death: 0.34.
- Estimated 12-month survival: 79% versus 53%.
Research significance: Demonstrates the potential of introducing a bispecific T-cell engager into first-line maintenance treatment for selected patients.
Regulatory status: Phase III results published; the study result is not itself an FDA approval for this specific combination and setting.
ARTEMIS-008: Risvutatug rezetecan in relapsed small-cell lung cancer
Results from the randomized Phase III ARTEMIS-008 study, presented at the IASLC 2026 World Conference on Lung Cancer, evaluated a B7-H3-directed antibody-drug conjugate against topotecan in relapsed small-cell lung cancer.
Reported results included:
- Median overall survival: 18.5 months versus 10.3 months.
- Hazard ratio for death: 0.46.
- Median progression-free survival: 7.2 months versus 3.0 months.
- Objective response rate: 58.3% versus 12.6%.
Research significance: Supports continued investigation of B7-H3 as a therapeutic target in small-cell lung cancer.
Evidence qualification: Conference-reported trial results. They should not be described as FDA-approved treatment or as independently established standard of care.
OptiTROP-Lung06: Sacituzumab tirumotecan + pembrolizumab
A Phase III study published in The New England Journal of Medicine evaluated sacituzumab tirumotecan plus pembrolizumab against chemotherapy plus pembrolizumab in previously untreated advanced non-squamous NSCLC without targetable genomic alterations and with PD-L1 expression below 1%.
At the reported interim analysis:
- Median progression-free survival: 15.0 months versus 5.7 months.
- Hazard ratio for progression or death: 0.49.
- Objective response rate: 50.2% versus 47.3%.
- Overall survival data were immature.
Research significance: Investigates an antibody-drug conjugate-based combination in a difficult-to-treat PD-L1-negative lung cancer population.
Regulatory status: Clinical trial publication, not an FDA approval.
5. Clinical Trial Monitoring List: Important Studies to Follow
The following studies and research programs provide a starting point for monitoring the clinical development of new cancer treatments.
INTerpath-001 — individualized melanoma vaccine
Trial ID: NCT05933577
Intervention: Intismeran autogene plus pembrolizumab.
Research question: Does adding a personalized neoantigen vaccine to pembrolizumab reduce recurrence following complete surgical resection of high-risk melanoma?
Latest finding: Positive Phase III primary and key secondary endpoints, with detailed results presented at ESMO 2026.
Monitoring priority: Overall survival, durability of recurrence-free survival, safety, regulatory submissions and potential approval.
NeoVax — personalized neoantigen vaccine in ovarian cancer
Trial ID: NCT04024878
Intervention: Personalized neoantigen-targeting peptide vaccine with an immunostimulant and delayed anti-PD-1 treatment.
Research question: Can patient-specific neoantigens be used to generate immune responses against high-grade epithelial ovarian cancer?
Latest finding: Published in Nature Medicine on October 14, 2026. The small Phase I study reported feasibility and safety findings and biomarker evidence suggestive of biological activity in six of ten patients.
Monitoring priority: Larger studies, feasibility of personalized vaccine manufacturing, durability of immune response and clinical outcomes.
DeLLphi-305 — tarlatamab in extensive-stage SCLC
Trial ID: NCT06211036
Intervention: Tarlatamab plus durvalumab.
Research question: Can a bispecific T-cell engager improve maintenance treatment outcomes following initial therapy?
Latest finding: Positive overall survival and progression-free survival results published in October 2026.
Monitoring priority: Long-term safety, confirmatory data, treatment sequencing and regulatory developments.
ARTEMIS-008 — B7-H3-directed ADC
Trial ID: NCT06498479
Intervention: Risvutatug rezetecan.
Research question: Can B7-H3-directed antibody-drug conjugate treatment improve outcomes in relapsed small-cell lung cancer?
Latest finding: Positive survival results reported at the 2026 IASLC World Conference on Lung Cancer.
Monitoring priority: Full publication, independent review, broader geographic validation and regulatory submissions.
6. Precision Oncology and Biomarker Research
Precision oncology uses tumor biology to guide cancer diagnosis and treatment. This is a key area of SmartCancer research because treatment response is influenced by molecular characteristics that may differ even among patients diagnosed with the same cancer type.
Biomarker monitoring categories
EGFR
Cancer focus: Non-small cell lung cancer.
Research focus: EGFR mutations, exon 20 insertions, acquired resistance, next-generation inhibitors and treatment sequencing.
KRAS and RAS pathway
Cancer focus: Pancreatic, colorectal and lung cancers.
Research focus: KRAS inhibitors, pan-RAS inhibitors, protein degradation, molecular combinations and resistance mechanisms.
HER2 / ERBB2
Cancer focus: Breast, gastric and lung cancers.
Research focus: HER2-directed antibodies, antibody-drug conjugates, HER2 mutations and treatment resistance.
ESR1
Cancer focus: Estrogen receptor-positive breast cancer.
Research focus: Acquired endocrine resistance, oral estrogen receptor degraders and combination treatment approaches.
BRCA1 / BRCA2 and HRR
Cancer focus: Breast, ovarian, prostate and pancreatic cancers.
Research focus: Homologous recombination deficiency, PARP inhibitors, DNA repair vulnerabilities and treatment sequencing.
MSI-H / dMMR
Cancer focus: Colorectal and other solid tumors.
Research focus: Immune checkpoint inhibitors, tissue-agnostic treatment and biomarker-guided patient selection.
FGFR2
Cancer focus: Cholangiocarcinoma and selected other cancers.
Research focus: FGFR inhibitors, gene fusions, rearrangements and acquired resistance.
RET and ROS1
Cancer focus: Lung cancer and selected solid tumors.
Research focus: Targeted kinase inhibitors, tissue-agnostic approvals and resistance mutations.
ctDNA and tumor mutational burden
Cancer focus: Multiple solid tumors.
Research focus: Molecular residual disease, tumor evolution, therapy response, recurrence and immunotherapy selection.
Research principle: Biomarker positivity is not equivalent to treatment eligibility in every case. The clinical significance of a molecular finding depends on the specific assay, cancer type, tumor context and approved indication.
7. Immunotherapy, CAR T-Cell Therapy and Antibody-Drug Conjugates
Immunotherapy remains one of the most important areas of cancer research. New studies are examining ways to activate immune responses, overcome tumor resistance and expand treatment to additional cancer types.
Key research categories
Immune checkpoint inhibitors
Track PD-1, PD-L1 and CTLA-4 therapies, combination regimens, immune resistance and biomarker-guided treatment selection.
Important questions: Which patients benefit most? Can treatment be moved earlier? How can durable response be achieved while reducing immune-related toxicity?
CAR T-cell therapy
Track new cellular targets, solid-tumor applications, manufacturing improvements, resistance and treatment-related toxicity.
Important questions: Can engineered immune cells penetrate solid tumors? How can treatment-related toxicities be reduced?
Bispecific T-cell engagers
These therapies are designed to connect immune cells with cancer cells through specific molecular targets.
Research focus: Tarlatamab, other bispecific antibodies, new tumor antigens and combination strategies.
Antibody-drug conjugates
ADCs combine a tumor-targeting antibody with a cytotoxic payload.
Research focus: HER2, TROP2, B7-H3, Nectin-4 and other targets; payload design, resistance and therapeutic combinations.
Oncolytic viral therapies
Research focuses on viruses modified to selectively infect cancer cells and stimulate an immune response.
Research focus: Combination with checkpoint inhibitors, treatment after immunotherapy resistance and new tumor-specific applications.
8. Personalized Cancer Vaccines and RNA Medicines
Personalized cancer vaccines are among the most closely watched developments in oncology.
These approaches identify mutations in a patient's tumor and use selected neoantigens to train the immune system to recognize cancer cells.
Major vaccine research priorities
- Individualized mRNA neoantigen vaccines.
- Personalized peptide vaccines.
- DNA-based cancer vaccines.
- Shared-antigen vaccines targeting recurring tumor mutations.
- KRAS-targeted cancer vaccines.
- Combination treatment with immune checkpoint inhibitors.
- Post-surgical vaccination to reduce recurrence risk.
Important 2026 developments
The INTerpath-001 Phase III melanoma results and the Phase I ovarian NeoVax publication are two significant milestones in personalized vaccine research. They represent different levels of clinical evidence and should be tracked separately.
The melanoma study provides late-stage evidence, whereas the ovarian study provides early-stage feasibility, safety and biological findings.
RNA medicines beyond vaccines
Research into RNA-based cancer medicines includes:
- mRNA for therapeutic protein production.
- siRNA for reducing selected disease-associated proteins.
- microRNA approaches to regulate gene expression.
- RNA aptamers for molecular targeting.
- Circular RNA as an experimental therapeutic platform.
Tracker priority: Follow clinical phase, tumor type, patient population, target neoantigens, immune response, recurrence-free survival, overall survival and regulatory submissions.
9. Liquid Biopsy, ctDNA and Minimal Residual Disease
Liquid biopsy is transforming research into tumor monitoring and molecular profiling by analyzing cancer-associated biological material in blood and other body fluids.
Five areas to monitor
1. Multi-cancer early detection
Blood-based technologies that attempt to identify molecular signals associated with more than one cancer type.
Research questions: Sensitivity, specificity, cancer localization, false positives, overdiagnosis and impact on mortality.
2. Molecular residual disease
Tests designed to detect small quantities of cancer-associated DNA remaining after surgery or other treatment.
Research questions: Does MRD status predict recurrence? Can MRD-guided treatment improve outcomes?
3. ctDNA treatment monitoring
Serial measurements of tumor-derived DNA to investigate treatment response and changes in tumor burden.
4. Resistance monitoring
Liquid biopsy may help identify emerging genetic alterations associated with acquired treatment resistance.
5. Tissue-of-origin research
Emerging approaches involving DNA methylation, fragmentomics and other molecular signals attempt to identify the likely origin of cancer-associated material.
Important: A liquid biopsy result must be interpreted in its clinical context. Multi-cancer screening tests are not interchangeable with approved cancer screening tests, and negative results do not exclude all cancers.
10. Artificial Intelligence in Cancer Research
AI is becoming an important analytical tool across oncology.
Research and clinical applications
- AI-assisted mammography and diagnostic imaging.
- Digital pathology and tumor classification.
- Genomic data analysis and biomarker identification.
- Drug discovery and protein-target prediction.
- Prediction of treatment response and resistance.
- Clinical trial matching and patient stratification.
- Integration of imaging, pathology and electronic health records.
AI research questions
SmartCancer should monitor AI tools based on their actual clinical performance rather than marketing claims.
- Was the system evaluated in a prospective clinical study?
- Was external validation performed?
- Was the dataset sufficiently representative?
- Does it improve diagnostic accuracy or patient outcomes?
- Does it reduce unnecessary procedures?
- Is there meaningful human clinical oversight?
Tracker priority: Record the specific AI tool, intended use, validation dataset, clinical setting, regulatory status and published performance results.
11. Cancer Resistance and Emerging Therapeutic Targets
Cancer resistance remains one of the major obstacles to durable treatment response.
Even when a targeted therapy initially works, cancer cells can adapt through additional mutations, altered signaling, changes in gene expression and interactions with the tumor microenvironment.
Therapeutic development areas
KRAS degradation
PROTACs and molecular glue approaches seek to direct selected proteins toward the cell's protein degradation machinery.
Targets to monitor: Mutant KRAS proteins and other difficult-to-target oncogenic proteins.
Next-generation RAS inhibitors
Research aims to target multiple RAS family proteins and address resistance to first-generation inhibitors.
Epigenetic therapies
Research into chromatin regulation, methylation and gene-expression control may reveal new therapeutic vulnerabilities.
Metabolic vulnerabilities
Cancer cells can reprogram cellular metabolism to support growth and survival. Researchers are studying metabolic pathways as potential therapeutic targets.
Tumor microenvironment
Research includes interactions among cancer cells, immune cells, blood vessels, extracellular matrix and surrounding tissues that influence tumor progression and treatment response.
12. 2027 Cancer Research Watchlist
The following topics form the forward-looking research agenda for the tracker. They are monitoring priorities, not predictions that a particular therapy will be approved in 2027.
Priority 1: Personalized mRNA cancer vaccines
Monitor additional Phase III data, regulatory submissions, recurrence outcomes and development in pancreatic, ovarian, breast and other cancers.
Priority 2: New RAS and KRAS therapeutic approaches
Monitor next-generation RAS inhibitors, protein degraders, combinations and mechanisms of acquired resistance.
Priority 3: Liquid biopsy and MRD-guided treatment
Monitor randomized clinical studies demonstrating whether ctDNA-guided decisions improve recurrence outcomes and survival.
Priority 4: Antibody-drug conjugates
Monitor new targets, payload technologies, resistance mechanisms and Phase III clinical results.
Priority 5: CAR T-cell therapy for solid tumors
Monitor advances in cellular engineering, tumor penetration, antigen selection and safety.
Priority 6: AI-powered oncology
Monitor prospective validation studies, FDA clearances and approvals, clinical performance and applications in pathology and radiology.
Priority 7: Metabolic cancer research
Monitor research involving glucose metabolism, insulin signaling, mitochondrial function, tumor metabolism and the interaction between metabolic health and cancer treatment.
Priority 8: Cancer prevention and interception
Monitor HPV-associated cancer prevention, genetic risk assessment, high-risk surveillance, precancerous conditions and biomarker-guided interception trials.
Priority 9: Immunotherapy combinations
Monitor checkpoint inhibitors, T-cell engagers, oncolytic viruses, therapeutic vaccines and rational combination regimens.
Priority 10: Treatment resistance and recurrence
Monitor ctDNA, MRD, new resistance mutations and evidence supporting changes in treatment sequencing.
13. Tracker Update Log
Every substantive update should be recorded to establish transparency and allow readers to follow the evolution of cancer research.
November 6, 2026 — Initial tracker publication
Established the FDA approvals section, selected Phase III trial records, early-phase vaccine research and the 2027 monitoring priorities.
Future updates — 2027
Add verified research developments, regulatory decisions, new trial readouts and changes in clinical evidence as they become available.
Standard tracker record format
Every new record should contain the following fields:
- Update date.
- Cancer type and histology.
- Research question or breakthrough.
- Drug, device or technology.
- Target or biomarker.
- Clinical trial phase and NCT number, where applicable.
- Study size and important endpoints.
- Results and limitations.
- FDA regulatory status and jurisdiction.
- Primary publication and independent supporting evidence.
14. Frequently Asked Questions
What is the Cancer Breakthroughs & Clinical Research Tracker?
It is a research monitoring resource that organizes important cancer developments across FDA approvals, clinical trials, precision oncology, immunotherapy, cancer vaccines, AI and emerging diagnostic technologies.
How often should the tracker be updated?
A practical editorial approach is to review FDA regulatory developments and major clinical research publications monthly, with a comprehensive review of the research categories at least quarterly.
What is the difference between an FDA-approved treatment and a Phase III trial?
An FDA-approved treatment has received regulatory authorization for a specified indication. A Phase III trial is a late-stage clinical investigation. Even a positive Phase III result does not automatically mean the treatment is approved.
Why are biomarkers important in cancer research?
Biomarkers can identify molecular characteristics of a tumor that may influence prognosis, treatment selection, resistance or eligibility for targeted therapies.
Are personalized cancer vaccines already established treatments?
Personalized neoantigen vaccines remain under investigation across several cancer types. Although important clinical results are emerging, they are not universally approved cancer treatments.
Can liquid biopsy replace tissue biopsy?
Not in every clinical situation. Liquid biopsy may complement tissue testing and provide useful information about tumor mutations and treatment response. Its suitability depends on the cancer type, test performance and clinical question.
Does a breakthrough mean a cancer cure has been discovered?
No. A breakthrough may describe a new research discovery, an improvement in clinical trial outcomes or a new regulatory approval. The effect on survival, quality of life and long-term outcomes must be evaluated separately.
Where can patients find cancer clinical trials?
Patients can search the US National Library of Medicine's ClinicalTrials.gov database and discuss appropriate trial eligibility with their oncology teams.
15. References and Research Databases
The tracker prioritizes primary regulatory notices, peer-reviewed medical publications, trial registries and scientific society publications.
- American Association for Cancer Research. AACR Cancer Progress Report 2026. Primary reference for the initial research framework, treatment developments and emerging technologies. Official report.
- US Food and Drug Administration. Oncology (Cancer)/Hematologic Malignancies Approval Notifications. Primary regulatory source for the selected FDA approvals in this tracker. FDA database.
- American Association for Cancer Research. FDA Approvals in Oncology: July–September 2026. AACR research update.
- European Society for Medical Oncology. First positive phase III trial data for an individualised mRNA-based neoantigen therapy. October 24, 2026. ESMO publication.
- The New England Journal of Medicine. Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer. October 2026. NEJM publication.
- International Association for the Study of Lung Cancer. Phase III ARTEMIS-008 trial results for risvutatug rezetecan. September 2026. IASLC publication.
- Nature Medicine. Sellars MC, Frank JA, Shim B, et al. Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial. October 14, 2026. DOI: 10.1038/s41591-026-04717-8. Read study.
- The New England Journal of Medicine. Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1-Negative Advanced NSCLC. October 25, 2026. DOI: 10.1056/NEJMoa2611280. Read study.
- ClinicalTrials.gov. Clinical trial registration and study-status database. Search clinical trials.
- PubMed. Biomedical literature and clinical research database. Search publications.
- National Cancer Institute. Cancer research, clinical trials and cancer information. NCI.
Editorial Policy and Medical Disclaimer
SmartCancer tracks scientific evidence independently of promotional claims. Company announcements and conference abstracts may be included when relevant, but are identified as such and are not treated as equivalent to peer-reviewed publications or regulatory approval.
Where possible, regulatory information is verified against FDA notices, clinical trial information against ClinicalTrials.gov, and research findings against primary scientific publications.
This tracker is for educational and research purposes only. It does not provide medical advice or recommend any specific treatment. Patients should consult qualified oncology professionals about diagnosis, biomarker testing, treatment decisions and clinical trial participation.
.png)
.png)
.png)
.png)
Comments
Post a Comment